Results 11 to 20 of about 265,106 (349)
Antisense oligonucleotides: recent progress in the treatment of various diseases
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background Antisense oligonucleotides are a promising novel class of therapeutic agents to treat different diseases in living things. They provide an efficient method for making target-selective agents because they change gene expression sequences ...
Chandravadivelu Gopi +2 more
doaj +1 more source
ACS Nano, 2020 A large-scale diagnosis of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is essential to downregulate its spread within as well as across communities and mitigate the current outbreak of the pandemic novel coronavirus disease 2019 ...
M. Alafeef, K. Dighe, P. Moitra, D. Pan
semanticscholar +1 more source
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Journal of Clinical Medicine, 2020 Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level ...
Karishma Dhuri +6 more
semanticscholar +1 more source
Molecules, 2021 The increase in antibacterial resistance is a serious challenge for both the health and defence sectors and there is a need for both novel antibacterial targets and antibacterial strategies.
Layla R. Goddard +9 more
doaj +1 more source
The powerful world of antisense oligonucleotides: From bench to bedside
Wiley Interdisciplinary Reviews - RNA, 2020 Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for personalized medicine. In the last decade, major chemical developments and improvements of the backbone structure of ASOs have transformed them into true approved ...
Anaïs M. Quéméner +5 more
semanticscholar +1 more source
Bioconjugated oligonucleotides: recent developments and thera-eutic applications [PDF]
Bioconjugate Chemistry, American Chemical Society, 2019, 30,
pp.366-383, 2020 Oligonucleotide-based agents have the potential to treat or cure almost any disease, and are one of the key therapeutic drug classes of the future. Bioconjugated oligonucleotides, a subset of this class, are emerging from basic research and being successfully translated to the clinic.
arxiv +1 more source
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Cells, 2020 The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in 1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was United States Food and Drug Administration (FDA) approved. This promises to
Sarah Bajan, G. Hutvagner
semanticscholar +1 more source
Modeling of nucleobase/oligonucleotide interaction with graphene and graphene oxide: the role of charging and/or oxidizing the graphene surface [PDF]
Mol. Cryst. Liq. Cryst. 2020, Vol. 697(1), 49-59, 2021 We analyze the influence of the charge and the degree of oxidation of the surface of graphene (Gr) on its interaction with cytosine and oligonucleotide r(C)10. This is a computational study involving DFT calculations and molecular dynamics simulations. It is shown that cytosine interacts stronger with graphene oxide (GO) than with Gr, while the energy ...
arxiv +1 more source
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases [PDF]
, 2018 Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient’s genetic ...
Fletcher, S. +6 more
core +5 more sources
In Vivo Models for the Evaluation of Antisense Oligonucleotides in Skin [PDF]
, 2022 Here, we describe an in vivo model in which antisense oligonucleotides were preclinically evaluated in reconstituted patient and healthy control skin.
Bremer, Jeroen, van den Akker, Peter C
core +1 more source